BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TAK-227 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TAK-227\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07298343-11360@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:TAK-227: Phase 2 readout est. (NCT07298343)
DESCRIPTION:TAK-227\, phase 2\, Celiac Disease.\nStudy: Evaluating the Effi
 cacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Di
 sease\nEstimated primary completion: August 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/tak-227#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07298343
URL:https://assetmemo.bio/drug/tak-227#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
